Emanuel Lohrmann

Boehringer Ingelheim

After studying medicine, Emanuel joined the Drug Discovery Department at Bayer Healthcare and then switched to the Drug Safety Department at Bayer in 2005, where he worked as a Drug Safety Scientist (Evaluation of ICSRs). Later he assumed responsibility for the risk management of a product in late-stage clinical development. In 2007, he became the Safety Risk Management Therapeutic Area Head in the Drug Safety Department at Bayer (TA Cardiovascular) within Global Drug Safety, responsible for the risk management of cardiovascular products under development and already on the market. In 2010, he joined CSL Behring as Head of the Risk Management Group within Global Drug Safety. He switched to Merck KGaA (Darmstadt) in 2013 as head of Global Drug Safety Science and Epidemiology, responsible for the pharmaco-epidemiology group in Global Drug Safety and the implementation of methods to improve signal management and benefit-risk assessment of products under development and post-approval. Since 2015 Emanuel is Lead Safety Physician in the Global Pharmacovigilance Group at Boehringer Ingelheim.